AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Breast carcinoma: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)NCT03036488 · results posted 2026-10-22 · Merck Sharp & Dohme LLC · 1174 people · tests Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · results posted 2026-09-29 · Seagen, a wholly owned subsidiary of Pfizer · 654 people · tests Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerNCT01547741 · results posted 2026-08-06 · NSABP Foundation Inc · 4242 people · tests Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantNCT03439046 · results posted 2026-07-10 · Novartis Pharmaceuticals · 287 people · tests Ribociclib, Letrozole, Alpelisib, Fulvestrant MRI and Mammography Before Surgery in Patients With Stage I-II Breast CancerNCT01805076 · results posted 2026-06-26 · Alliance for Clinical Trials in Oncology · 319 people · tests Breast surgery, Magnetic resonance imaging, Mammography Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerNCT05113251 · results posted 2026-06-09 · AstraZeneca · 927 people · tests Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab Prospective Randomized Study of Accelerated Radiation Therapy (PRART)NCT04175210 · results posted 2026-05-07 · Weill Medical College of Cornell University · 397 people · tests Radiation therapy - 3 weeks, Radiation therapy - 2 weeks Evaluation in the Treatment of Neuropathic Pain Post Breast SurgeryNCT03794388 · results posted 2026-05-05 · Institut Cancerologie de l'Ouest · 140 people · tests Capsaicin, Pregabalin Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · results posted 2026-02-24 · Alliance for Clinical Trials in Oncology · 898 people · tests Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory B… Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerNCT02947685 · results posted 2026-02-12 · Alliance Foundation Trials, LLC. · 518 people · tests palbociclib, trastuzumab, pertuzumab, letrozole A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)NCT05104866 · results posted 2026-02-04 · AstraZeneca · 732 people · tests Dato-DXd, Capecitabine, Gemcitabine, Eribulin A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerNCT05654623 · results posted 2026-02-03 · Pfizer · 624 people · tests ARV-471, Fulvestrant
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.J Clin Oncol 2026 · PMID 42928710 ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.Nature 2026 · PMID 42927884 Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 …Ann Oncol 2026 · PMID 42927858 From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.Ann Oncol 2026 · PMID 42927857 Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label…Ann Oncol 2026 · PMID 42927856 Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carc…Ann Oncol 2026 · PMID 42927855 Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE rando…Ann Oncol 2026 · PMID 42927854 A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Re…Ann Oncol 2026 · PMID 42927853 Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer …Lancet Oncol 2026 · PMID 42927765 Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136 Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann Oncol 2026 · PMID 42926111
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA
PaclitaxelPaclitaxel · updated 2026-09-09 · Teva Parenteral Medicines, Inc. CyclophosphamideCyclophosphamide · updated 2026-09-03 · Nexus Pharmaceuticals, LLC Cyclophosphamide For InjectionCyclophosphamide · updated 2025-04-02 · Slate Run Pharmaceuticals, LLC

An update is not always a new approval — open the label to see what changed.

Want these every week? Follow breast carcinoma and get a note on your phone with the new trials and papers.

🔔 Follow breast carcinoma
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy